MACE y TEV en los programas de ensayos clínicos de upadacitinib en artritis reumatoide, artritis psoriásica y espondilitis anquilosante
RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392
Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.
This study by Charles-Schoeman, et al. analysed the results of upadacitinib trials and compared the incidence of MACE and VTE events in RA, PsA and AS. Zero MACE and one VTE event was recorded in AS, so it was excluded from further analysis.
Keywords:
